Spatial and Molecular Architecture of Tumor Environments Responsive to IO (immuno-oncology) Therapy

Overview

About this study

The purpose of this study is to gain stepwise understanding of the fundamental biology governing human antitumor immunity, by systematic study of the tumor-immune interface at the level of the TME, taking advantage of the heterogeneity of different interacting tumor and immune cell subsets.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • 18 years of age orolder
  • Histologic proof of malignancy, including metastatic melanoma and metastatic non-smallcell lungcancer
  • CT or PET/CT evidence of measurable lymph node involvement, 2-4cm in size in the longest diameter
  • Recommendation by the treating provider to initiate therapy with a commercially available, FDA approved, anti-PD-1-based therapy or anti-PD-L1therapy
  • The ability and willingness to sign an informed consent

Exclusion Criteria:

  • Pregnancy or lactation (forfemales); pregnancy test will have been completed as per standard of care prior to treatment and does not need to be repeated for this study
  • Inability on the part of the patient to understand the informed consent or be compliant withthe protocol
  • Previous adjuvant immunotherapy with immune checkpointinhibitor(s)
  • Previous systemic immune checkpoint inhibitor(s)therapy
  • Other active malignancies within 3years
  • Any conditions, which in the opinion of the patient’s treating oncologist, or the provider performing the biopsy procedure, would make participation in this protocol unreasonably hazardous for the patient (including a history of bleeding disorder and a serious or life- threatening allergic reaction to such local anesthetics as lidocaine orxylocaine)

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Svetomir Markovic, M.D., Ph.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20358111

Mayo Clinic Footer